35 results about "Vascular graft" patented technology

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, done or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts ("TEVGs") in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

Synthetic hemocompatible vascular grafts manufactured from polyvinyl alcohol-based biomaterials containing crystalline segments of polyvinyl alcohol, which are long-term fully functioning vascular grafts that provide no activity towards immune systems in recognizing surfaces as foreign bodies that would normally lead to fibrosis, platelet activation and subsequent thrombi formation, and thus occlusion of the grafts.

The invention disclosure provides a composite compliant vascular graft for implantation in a host, which graft includes a tubular body having a lumen and a tubular wall surrounding the lumen made of a composite material, which is adapted to permit expansion of the tubular body from a native state to an expanded state and then to return to the native state in response to pressure changes in the lumen, which includes a mechanical component which is adapted to limit the expanded state, and a compliant component which is adapted to bias return of the tubular body to the native state.

The application discloses an anti-bending artificial blood vessel, which comprises an artificial blood vessel inner layer, a synthetic polymer anti-bending ring and an artificial blood vessel outer layer; the artificial blood vessel inner layer is a synthetic polymer tube body; the artificial blood vessel outer layer is a synthetic polymer fiber membrane; the shape of the synthetic polymer anti-bending ring is a non-equidistant spiral structure; the synthetic polymer anti-bending ring is wound on the outer wall of the artificial blood vessel inner layer, is between the artificial blood vessel inner layer and the artificial blood vessel outer layer, and is fixed by being covered by the artificial blood vessel inner layer and the artificial blood vessel outer layer. The application further discloses a preparation method of the artificial blood vessel. The application can make the artificial blood vessel to be bent by 180 degrees in a full ring without flat collapse and kinking, can ensure that the whole artificial blood vessel has good anti-bending performance, can effectively improve the anti-bending performance of the artificial blood vessel, and can effectively improve the compliance of the artificial blood vessel.

The application discloses a medical instrument technical field, and relates to an integrated type artificial blood vessel with a sinus, which comprises a tube part, a sinus-tube joint and a sinus part which are integrally woven and shaped, and the tube part and the sinus part have a same longitudinal axis, the sinus part has a dense structure which is composed of upper and lower layer fabric tissues which are connected with each other, and the connecting points are located at the overlapping positions of the upper and lower layer tissue points, the fabric coverage of the dense structure is 80%-95%, the upper and lower layer fabric tissues are both woven by a plurality of fabric tissues with a yarn density of not less than 80 root / cm, and the upper and lower layer fabric tissues both contain twill tissues. The application provides an integrated type artificial blood vessel with a sinus, which has a good sinus part form, a dense structure and good stability, the sinus part has a dense tissue structure, so that the elastic performance is ensured, the structure support is strong, the long-term radial overexpansion can be prevented, the service life of the artificial blood vessel and the autologous valve is prolonged, and the possibility of postoperative secondary intervention is reduced.

The disclosed concept includes the use of additive and / or subtractive manufacturing of mesoporous structures on two-dimensional sheets that are mechanically tunable, to provide a vascular graft that controls biodegradable graft host interactions, to improve graft patency and functionality long-term. The vascular graft includes the two-dimensional sheets in a rolled or tubular configuration to form a lumen wherein a surface and / or bulk modification is applied to the flat sheet. In addition, a plurality of mesoporous structures (e.g., gaps) are formed in the flat sheet using a subtractive manufacturing technique.

A vascular graft deployment tool can include a handle, an elongate mandrel positioned distal to the handle, a vascular graft at least partially disposed coaxially about the mandrel, a sheath assembly including a distal sheath portion and a proximal sheath portion, wherein the distal and proximal sheath portions are configured to constrain the vascular graft against the mandrel at an insertion diameter, and an actuator movable relative to the handle and engaging the sheath assembly, wherein operation of the actuator causes at least one of the distal and proximal sheath portions to longitudinally separate to free at least a portion of the vascular graft. Further, the vascular graft is expandable from an insertion state to a deployed state, and at least two suture envelopes are positioned between opposite end portions of the vascular graft.

The present disclosure relates to an implantable vascular graft material, including: a substrate including a graft material, the substrate defining a top surface and a bottom surface; and one or more bispecific binding partners having a luminal binding domain bound to the top surface and one or more cellular binding domains. In embodiments, the disclosure includes an implantable vascular graft including: a tubular base layer including a graft material, the tubular base layer defining a luminal surface and an abluminal surface; and a fusion peptide having a heparin binding domain bound to the luminal surface and one or more monocyte binding domains. In embodiments, the present disclosure provides one or more implantable vascular grafts such as A-TEVs, methods of making vascular grafts, methods of use, and the like.

Provided herein are methods of generating optimized models of vascular grafts for subjects in certain embodiments. Methods of treating subjects in need of vascular grafts are also provided. Related systems and computer program products are additionally provided.

The invention provides a small-caliber blood vessel biological scaffold capable of adjusting stress relaxation and a preparation method of the small-caliber blood vessel biological scaffold. The biological scaffold is of a tubular structure which is formed by arranging micron fibers and nanofibers in a crossed mode, is arranged in a net shape and is provided with a layered tube wall. The small-caliber blood vessel biological scaffold has adjustable stress relaxation performance, biodegradability, bionic viscoelasticity and excellent surgical suture performance, endogenous cells can be guided to be clustered and self-assembled, a small-caliber blood vessel graft with the deformation behavior close to that of a natural blood vessel is formed, and the small-caliber blood vessel biological scaffold has the advantages of being simple in structure and convenient to use. And the double bottleneck that the mechanical property and the tissue regeneration function of the traditional stent are difficult to consider is solved.

Current approaches in small diameter vascular grafts for coronary artery bypass surgeries fail to address physiological variations along the graft that contribute to thrombus formation and ultimately graft failure. An interlayer drug delivery system can sustain delivery of heparin through the graft with a high degree of temporal and spatial control. A heparin-loaded gelatin methacrylate interlayer sits between a biohybrid composed of decellularized bovine pericardium and poly(propylene fumarate) and UV crosslinking is controlled via 3D printed shadow masks. The masks enable control of the resultant gelMA crosslinking and properties by modulating the incident light intensity on the graft. High doses of heparin have detrimental effects on endothelial cell function. When exposed to heparin in a slower, more sustained manner consistent with the masks, endothelial cells behave similarly to untreated cells. Slower release profiles cause significantly more release of tissue factor pathway inhibitor, an anticoagulant, than a faster release profile.

The invention provides a composite membrane for vascular transplantation and a preparation method of the composite membrane. The composite membrane comprises stacked degradable coatings, the degradable coatings comprise a first degradable coating, a second degradable coating, a third degradable coating and a fourth degradable coating; each layer of degradable coating comprises a drug sustained-release matrix and a drug dispersed in the drug sustained-release matrix; the drug sustained-release matrix is a PVA (Polyvinyl Alcohol) film; the medicines comprise antibiotics and / or antibacterial agents. The composite membrane for vascular transplantation has good drug controlled release ability, has high anti-infection and anti-adhesion ability, is almost suitable for all types of vascular grafts, and breaks through the limitation of a coating technology in application.

The present disclosure describes a system and a method for producing patient-specific small diameter vascular grafts (SDVG) for coronary artery bypass graft (CABG) surgery. In some embodiments, the method for producing SDVGs includes non-invasive quantification of patient-specific coronary and vascular physiology by applying computational fluid dynamics (CFD), rapid prototyping, and in vitro techniques to medical images and coupling the quantified patient-specific coronary and vascular physiology from the CFD to computational fluid-structure interactions and SDVG structural factors to design a patient-specific SDVG.

An access device for a vascular graft is disclosed. The access device can allow two large-diameter medical devices to be inserted at the same time. The access device may include a body defining a common arm, a first proximal arm, and a second proximal arm. The common arm may include a common lumen extending from a distal end of the common arm to a proximal end of the common arm. The first arm may include a first lumen extending from a proximal end of the first arm to the common lumen. The second arm may include a second lumen extending from a proximal end of the second arm to the common lumen. The access device may include a plurality of hemostasis valves. A first hemostasis valve may be disposed at a proximal end of the first proximal arm. A second hemostasis valve may be disposed at a proximal end of the second proximal arm.

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, alone or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts (“TEVGs”) in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

A vascular graft device (1), comprising a liner (3) comprising a microporous structure made from a first polymer material, wherein the first polymer material is hemocompatible; and a structural scaffold (5) supporting the liner (3), wherein the structural scaffold (5) comprises a macroporous fiber structure (50), made from a second polymer material wherein the second polymer material is biodegradable.

The present disclosure relates to inhibition of platelet absorption. Cardiovascular grafts with highly reduced thrombosis are provided. The cardiovascular graft is an electrospun nonwoven web produced from a supramolecular polymer of large diameter fibers. The cardiovascular graft can be implanted in a human body as a vascular graft to allow blood vessel bypass / reconstruction, or repeated venous access for dialysis treatment, as well as other small diameter vascular disorders.

It has been determined that optimizing cell seeding on tissue engineered vascular grafts (TEVGs) is associated with reduced inflammatory response and reduced post-operative stenosis of the TEVG. Cell seeding increases TEVG patency in a dose-dependent manner, and the more cells seeded, the better the TEVG patency, however, incubation duration exhibits minimal effect on TEVG patency. Methods of engineering patient-specific TEVGs are provided, including optimal cell numbers for maintaining graft patency and reducing post-operative stenosis. A closed, disposable customizable system for seeding TEVGs is also provided. To enhance the efficacy of cell seeding, the system is preferably custom designed based on the morphology of the patient-specific graft.

The present invention relates generally to shape memory polymer devices that are porous. The porosity of the device may generate advantageous neovascularization, decrease inflammation, and decrease fibrosis. The device may include a surface having a pore size of 400 μm-1200 μm and a pore spacing of about 100 μm to about 750 μm.

An apparatus and method are disclosed for detecting the disconnection of a vascular access device such as a needle, cannula or catheter from a blood vessel or vascular graft segment. A pair of electrodes is placed in direct contact with fluid or blood in fluid communication with the vascular segment. In one embodiment, the electrodes are incorporated into a pair of connectors connecting arterial and venous catheters to arterial and venous tubes leading to and from an extracorporeal blood flow apparatus. Wires leading from the electrodes to a detecting circuit can be incorporated into a pair of double lumen arterial and venous tubes connecting the blood flow apparatus to the blood vessel or vascular graft. The detecting circuit is configured to provide a low-voltage alternating current signal to the electrodes to measure the electrical resistance between the electrodes, minimizing both the duration and amount of current being delivered. Detection of an increase in electrical resistance between the electrodes exceeding a pre-determined threshold value may be used to indicate a possible disconnection of the vascular access device.

Disclosed herein are devices having an inner core comprising a biomatrix; and an outer scaffold comprising a biocompatible polymer. Also disclosed herein are methods for supporting a blood vessel and / or for treating or preventing an aneurysm by disposing a device having an inner core comprising a biomatrix; and an outer scaffold comprising a biocompatible polymer on an outer surface of a blood vessel of a subject. The bioengineered scaffolds of the present disclosure can limit the progression of vessel dilation while maintaining the biochemical characteristics of the vessel wall. Furthermore, the disclosed devices provide a minimally invasive alternative to conventional graft replacement, making the device suitable for patients having comorbidities.

The present invention relates to a vascular graft, and more particularly, to a vascular implant having a sulfide-based structure for minimizing inflammation and for encouraging cell tissue regeneration. It describes a design of coaxial nanofibrous systems with slow release H2S to reduce inflammation and encourage cell tissue regeneration.

The present invention relates to a medical device, specifically to a subcutaneous tunneler assembly for artificial vascular arteriovenous fistulas, which includes a dilator, a guidewire, and a sleeve. The dilators are two open-ended, tubular structures, each with a bendable segment. The sleeve has a sleeve cavity that fits the artificial vascular graft. The guidewire is placed in the communicating cavity formed by the abutment of the two dilators. The bendable segments bend the two dilators to fit a predetermined path of the subcutaneous tunnel. After the dilators are introduced subcutaneously through a skin incision, the ends are abutted to form a continuously curved U-shaped subcutaneous tunnel, reducing the size of the skin incision, minimizing surgical trauma, and preventing infection. The sleeve protects the artificial vascular graft from contact with the skin, reducing the risk of infection during surgery. After the artificial vascular graft is inserted into the sleeve, there is no need to adjust its position, preventing twisting, bending, or bending of the artificial vascular graft during insertion.

The application belongs to the technical field of medical material preparation, and discloses a collagen-based artificial integrated composite blood vessel graft, a preparation method and application. The composite blood vessel graft is prepared by compounding a collagen tubular support and a polymer tubular framework. The collagen support is formed by electrochemical deposition and directional induction of self-assembly of type I collagen protein, the inner layer is an axial orientation dense structure (simulating the blood vessel endothelium), the middle layer is a ring / axial orientation loose porous structure (porosity 40-80%, interlayer spacing 20-100 mu m), and the thickness and inner diameter are controllable; the polymer framework is prepared by melt electrostatic direct writing, and the graft is given the characteristics of sutured, axial tensile and radial anti-expansion, and is adapted to the mechanical characteristics of the host vessel. The graft can guide the directional growth of endothelial cells / smooth muscle cells, form a layered structure and remodel the regenerated blood vessel, and maintain long-term patency.

The invention discloses application of an STAT1 inhibitor and a detection preparation and a construction method of a vascular transplantation remodeling model, and belongs to the technical field of transplantation vascular remodeling treatment and diagnosis. The STAT1 is used as a target spot for preventing, treating and / or relieving the transplanted vascular remodeling and related diseases, meanwhile, the STAT1 is used as a biomarker for diagnosing the transplanted vascular remodeling, and a new thought is provided for preventing, treating and / or relieving the transplanted vascular remodeling and the related diseases.

To provide devices and methods useful for securing a graft material to a body structure.SOLUTION: Vascular graft 107 includes at least one conduit having a first conduit region and a second conduit region, at least one perturbation formed in the conduit in the second conduit region and configured to cause a vortex in the second conduit region.SELECTED DRAWING: Figure 2

Described herein are variations of implantable matrices that produce pharmaceuticals for the treatment of chronic diseases. For example, the implantable matrix can include a vascular graft of human acellular vasculature coated with cells. The cells can be engineered to produce pharmaceuticals capable of treating chronic diseases. The cell-seeded matrix can be implanted adjacent to a patient's blood vessels so that pharmaceuticals produced by the cells are readily released into the patient's bloodstream. Additionally, or alternatively, the cell-seeded matrix can treat chronic diseases in an environment local to the implantation site. Also described herein are methods for making and using such implantable matrices.

A disposable thrombectomy maceration and aspiration system for macerating and aspirating thrombus or other obstructive material in a lumen of a vascular graft or vessel. The system includes three major components: a disposable integrated aspiration pump and fluid collection device for generating aspiration vacuum pressure and collecting macerated particulate, a disposable integrated thrombectomy and aspiration apparatus removably coupled to the device configured to macerate the thrombus with a motor powered maceration wire while including an aspiration pathway for aspirating the macerated particulate into the device, and a catheter removably coupled to the apparatus and covering a portion of the maceration wire for insertion into the patient to the thrombus site. The catheter is of sufficient size to allow the macerated particulate to be aspirated from a distal opening through the catheter and apparatus before being deposited into the fluid collection compartment of the device.

System, apparatus, and method for replacing a segment of vasculature, tissue, or organ.